Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Sickle Cell Disease
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Louisville, Kentucky • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Pre-treatment Loss of Independent Activities of Daily Living
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced May 21, 2026, 10:00 PM EDT
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Radiation Tolerance, Skin Aging, Rhytids
Interventions
LED GentleWaves®
Device
Lead sponsor
L'Oreal
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2009 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions
Donor CD34+ and CD3+ cells
Biological
Lead sponsor
Jeffrey Veale, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Breast Cancer, Cognitive Ability, General, Fatigue, Pain, Psychosocial Deprivation, Radiation Toxicity, Skin Abnormalities
Interventions
DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay, flow cytometry, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, assessment of therapy complications, quality-of-life assessment, 3-dimensional conformal radiation therapy, breast irradiation, external beam radiation therapy, hypofractionated radiation therapy, intensity-modulated radiation therapy, whole breast irradiation
Genetic · Other · Procedure + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
Discussion, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced May 21, 2026, 10:00 PM EDT
Terminated No phase listed Observational
Conditions
Radiation Tolerance
Interventions
Exposure to irradiation
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total lymphoid irradiation
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total Lymphoid irradiation
Biological · Radiation
Lead sponsor
Stephan Busque
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Advanced Cancer
Interventions
4-Demethyl-4-cholesteryloxycarbonylpenclomedine
Drug
Lead sponsor
DEKK-TEC, Inc.
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
New Orleans, Louisiana • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced May 21, 2026, 10:00 PM EDT
Conditions
Immune Tolerance
Interventions
Immune tolerance after kidney transplant, Donor blood stem cells and T cells
Procedure · Drug
Lead sponsor
Samuel Strober
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced May 21, 2026, 10:00 PM EDT